INTENATIONAL SEARCH REPORT

International application No. PCT/KR 2005/000329

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07K 7/06, C07K 5/11, C07K 5/117, C07K 5/097, A61K 38/06, A61K 38/07, A61K 38/08 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC^7 : C07K, G01N, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Genbank, STN Reg., NCBI Blast (NR)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPI, EPODOC, PubMed, Genbank, STN Reg., NCBI Blast (NR)

| ategory* | Citation of document, with indication, where app | ropriate, of the relevant passages | Relevant to claim No. |
|--|---|--|--|
| A | US2003/0096260A1 (ZHENHUA MIAO (22.05.2003) | et al.) 22 May 2003 | 1-11, 20 |
| x | *the whole document.* *claim 22.* | | 18, 19 |
| A | US 2003/0203841A1 (JI MING WANG (30.10.2003) *the whole document.* | et al.) 30 October 2003 | 1-11, 18-20 |
| | | | |
| X Further | documents are listed in the continuation of Box C. | See patent family annex. | |
| "A" docume to be of "E" earlier : filing d "L" docume cited to special "O" docume means "P" docume | categories of cited documents: ent defining the general state of the art which is not considere particular relevance application or patent but published on or after the internationa ate ent which may throw doubts on priority claim(s) or which to establish the publication date of another citation or othe reason (as specified) ent referring to an oral disclosure, use, exhibition or othe ent published prior to the international filing date but later tha ority date claimed | to understand the principle or the comment of particular relevents of an inventive step when the document of particular relevents of particular relevants of particular releva | with the application but city cory underlying the invention ance; the claimed invention annot be considered to involument is taken alone ance; the claimed inventive an inventive step when to one or more other subeing obvious to a persument of the control of the |
| Date of the | actual completion of the international search 30 May 2005 (30.05.2005) | Date of mailing of the international s 15 June 2005 (1 | earch report 5.06.2005) |
| | mailing address of the ISA/AT Austrian Patent Office resdner Straße 87, A-1200 Vienna | Authorized officer GÖRNER | W. |
| | No. +43 / 1 / 534 24 / 535 | Telephone No. +43 / 1 / 534 24 | . / 558 |

INTERNATIONAL SEARCH REPORT

International application No. PCT/KR 2005/000329

| ategory* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| | Original of document, with indication, where appropriate, of the relevant passages | Rejevant to claim No. |
| Α | Bae YS, et al. "Differential activation of formyl peptide receptor-like 1 by peptide ligands." J Immunol. 2003, Vol. 171, No.12, pp. 6807-13. [retrieved from the Journal of Immunology online] [retrieved from the internet on 24 May 2005 (24.05.2005)] http://www.jimmunol.org/cgi/reprint/171/12/6807 > | 1-11, 18-20 |
| | *the whole document, page 6808, 2nd column, 2nd paragraph.* | |
| | | |
| A | Bae YS, et al. "Differential activation of formyl peptide receptor signaling by peptide ligands." Mol Pharmacol. 2003, Vol. 64, No. 4, pp. 841-7. [retrieved from Molecular Pharmacology online] [retrieved from the internet on 24 May 2005 (24.05.2005)] http://molpharm.aspetjournals.org/cgi/reprint/64/4/841 | 1-11, 18-20 |
| | *the whole document.* | |
| | <u> </u> | |
| P,X | Bae YS, et al. "Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling." J Immunol. 2004, 173, No. 1, pp. 607-14. | 1-11, 18-20 |
| | (Abstract) NCBI PubMed [online] [retrieved from the internet on 24 May 2005 (24.05.2005)] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_ids=15210823&query.hl=7> | |
| | 24 May 2005 (24.05.2005)] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db | |
| | 24 May 2005 (24.05.2005)] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&listuids=15210823&query.nl=7 | |
| | 24 May 2005 (24.05.2005)] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&listuids=15210823&query.nl=7 | |
| | 24 May 2005 (24.05.2005)] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&listuids=15210823&query.nl=7 | |
| | 24 May 2005 (24.05.2005)] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&listuids=15210823&query.nl=7 | |
| | 24 May 2005 (24.05.2005)] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&listuids=15210823&query.nl=7 | |
| | 24 May 2005 (24.05.2005)] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&listuids=15210823&query.nl=7 | |
| | 24 May 2005 (24.05.2005)] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?crmd=Retrieve&db =pubmed&dopt=Abstract&listuids=15210823&queryn =7> *abstract.* | |
| | 24 May 2005 (24.05.2005)] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?crmd=Retrieve&db=pubmed&dopt=Abstract&listuids=15210823&querynl=7> *abstract.* | |
| | 24 May 2005 (24.05.2005)] *abstract.* </td><td></td></tr><tr><td></td><td>24 May 2005 (24.05.2005)] *abstract.* | |
| | 24 May 2005 (24.05.2005)] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?crmd=Retrieve&db=pubmed&dopt=Abstract&listuids=15210823&query.hl=7> *abstract.* | |
| | 24 May 2005 (24.05.2005)] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?crmd=Retrieve&db=pubmed&dopt=Abstract&listuids=15210823&query.hl=7> *abstract.* | |
| | 24 May 2005 (24.05.2005)] | |

INTERNATIONAL SEARCH REPORT

International application No. PCT/KR 2005/000329

Continuation of first sheet

Continuation No. I:

Nucleotide and/or amino acid sequence(s)

(Continuation of item 1.b of the first sheet)

- 1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
- a. type of material: a sequence listing
- b. format of material: in written format
- c. time of filing/furnishing: contained in the international application as filed

Continuation No. II:

Observations where certain claims were found unsearchable

(Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

Claims Nos.: 13-17 because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 13 to 15 and 17 are directed to methods of treatment of the human or animal body, the subject matters of claims 13 to 15 and 17 were included in the search based on the alleged effects of the disclosed peptide compounds, but no establishment of novelty, inventive step and industrial application of the subject matters of claims 13 to 15 and 17 was carried out.

Claim 16 is directed to a method of preventing binding between A β 42 and human neutrophils through peptides according to the subject matters of claims 1-11. Since this formulation does not exclude a potential treatment of the animal or human body, the subject matter of claim 16 was searched as described above but had to be excluded from the establishment of novelty, inventive step and industrial application of the subject matters of claim 16.

Claims Nos.: 12, 16, 20 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

INTERNATIONAL SEARCH REPORT

International application No. PCT/KR 2005/000329

1) Claim 12 is directed to "A W-rich peptide mimic". Since no such substances are disclosed in the application, neither the search nor the establishment of novelty, inventive step and industrial application of the subject matters of claim 12 were carried out.

2)The parts of claims 16 and 20 which refer to "a W-rich peptide mimic" lack disclosure since no peptide mimic is described in the application. Therefore, these parts of claims 16 and 20 had to be excluded from the search as well as the establishment of novelty, inventive step and industrial application of the subject matters of claims 16 and 20.

INTERNATIONAL SEARCH REPORT Information on patent family members

Intermonal application No. PCT/KR 2005/000329

| | Patent in s | document cited search report | Publication date | Patent family member(s) | Publication date |
|----|----------------|---------------------------------|---------------------|-------------------------|------------------|
| | А | | | none | |
| us | A | 20030096 260 | | none | |
| | | | | | |
| | | | | | |
| | | | | | • |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | • | | |
| | | | | | |
| | | | | | |
| | | | | , | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |